Written Question · S4W-06006 · Session 4
On what basis it decided to exclude prostate cancer from its Detect Cancer Early Initiative.
The question
To ask the Scottish Executive on what basis it decided to exclude prostate cancer from its Detect Cancer Early Initiative.
The answer
The Scottish Government is committed to taking forward a Detect Cancer Early Programme with a target of increasing the number of cancers detected at the early stage of disease as the earlier that cancer is diagnosed, the better the chance of a complete cure. The programme is directed at lung, breast and colorectal cancers in the first instance as these cancers represent 45% of all cancers diagnosed in Scotland per year. This will enable us to have the greatest impact both in terms of patient numbers and in addressing cancer in areas if deprivation where survival has historically been poorest.
Early diagnosis and high quality treatment and care for all patients with cancer is a top priority and although we have not included prostate cancer in this initial programme, we anticipate that the programme will benefit other groups of people as it is rolled out. Raised awareness of all cancers amongst the public and health practitioners are expected to result in earlier presentation, referral and assessment for all those with a possibility of cancer. The increased diagnostic capacity which will be generated by the programme will provide benefits to a wider group of patients in terms of improved access to a variety of tests.
Early diagnosis and high quality treatment and care for all patients with cancer is a top priority and although we have not included prostate cancer in this initial programme, we anticipate that the programme will benefit other groups of people as it is rolled out. Raised awareness of all cancers amongst the public and health practitioners are expected to result in earlier presentation, referral and assessment for all those with a possibility of cancer. The increased diagnostic capacity which will be generated by the programme will provide benefits to a wider group of patients in terms of improved access to a variety of tests.
In the Official Report
No contribution in the Official Report cites S4W-06006 by reference.